Abstract
Background. Lung cancer continues to be in the leading positions in mortality among all malignant neoplasms; 85 % of all cases are nonsmall cell lung cancer (NSCLC), and in 40 % of patients the process is diagnosed at a common unresectable stage. Chemoradiotherapy is the standard of treatment for this category of patients, which allows to improve the results of local control and overall survival. In Russia, chemoradiotherapy accounts for about 4 % of all treatment methods. Perhaps this is due to high toxicity of this method and, as a result, a deterioration in quality of life of patients.Aim. To assess the quality of life of patients with locally advanced NSCLC during simultaneous chemoradiotherapy in combination with and without accompanying immunotherapy.Materials and methods. The study included 60 patients with locally advanced NSCLC. The study group (n = 30) received a radical course of simultaneous chemoradiotherapy with the use of accompanying immunotherapy with azoximer bromide. Patients in the control group (n = 30) underwent a course of simultaneous chemoradiotherapy in the standard mode. We evaluated the criteria of quality of life in patients using questionnaires EORTC QLQ-LC13, EQ-5D-5L, EORTC QLQ-C30.Results. In the study group, an improvement in most of the parameters of quality of life and a decrease in the severity of symptoms were demonstrated compared with the control group.Conclusion. The study demonstrated a tendency to reduce hematological toxicity and improve the quality of life of patients with NSCLC. This allows us to consider the possibility of using accompanying immunotherapy in combination with chemoradiotherapy as an additional therapeutic option that improves the quality of life of patients and the tolerability of the treatment.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call